The purpose of this study is to estimate the risk of myocardial infarction (MI)/coronary death associated with use of monotherapy low dose ASA (single antiplatelet) as well as concomitant use of monotherapy low dose ASA and proton pump inhibitors (PPIs) in patients with serious coronary heart disease using two UK primary care databases.
Number of Anticipated Subjects: In case-control analysis: 10.000-15.000 participants
Study Type
OBSERVATIONAL
Enrollment
42,542
Research Site
Madrid, Spain
Research Site
Mölndal, Sweden
Nonfatal MI or coronary death
Time frame: Up to eight years from entry into study cohort
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.